SELLAS Life Sciences Group, Inc. — Director's Dealing 2011

Jan 14, 2011

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RXI PHARMACEUTICALS CORP (RXII)
CIK: 0001390478
Period of Report: 2011-01-13

Reporting Person: Hillsberg Sanford (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2011-01-13	Stock Option	$2.31	A	50000	Acquired	2021-01-13	Common Stock (50000)	Direct

Footnotes

F1: Granted pursuant to the RXi Pharmaceuticals Corporation 2007 Incentive Plan.

F2: Per share.

F3: The options will vest in equal quarterly installments of 12,500 on each of March 31, 2011, June 30, 2011, September 30, 2011 and December 31, 2011.